Cosmo Pharmaceuticals N.V. (CMOPF)
USD 66.93
(0.0%)
USD 66.93
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 92.78 Million | 110.81 Million | 77.07 Million | 73.77 Million | 71.78 Million | 76.85 Million |
| Cost of Revenue | 18.83 Million | 48.26 Million | 43.51 Million | 33.42 Million | 28.77 Million | 25.83 Million |
| Gross Profit | 73.94 Million | 62.54 Million | 33.56 Million | 40.34 Million | 43 Million | 51.01 Million |
| Operating Expenses | 47.29 Million | 34.14 Million | 21.38 Million | 39.06 Million | 58 Million | 71.52 Million |
| Selling, General and Administrative Expenses | 30.79 Million | 21.61 Million | 12.38 Million | 22.6 Million | 40.59 Million | 59.3 Million |
| Research and Development Expenses | 18.81 Million | 12.53 Million | 8.99 Million | 16.45 Million | 17.41 Million | 12.21 Million |
| Other Expenses | -2.31 Million | - | - | - | - | - |
| Cost and Expenses | 86.63 Million | 82.41 Million | 64.9 Million | 72.49 Million | 86.78 Million | 97.35 Million |
| Operating Income | 6.14 Million | 28.39 Million | 12.17 Million | 1.27 Million | -15 Million | -20.5 Million |
| Interest Expense | 8.52 Million | 10.06 Million | 11.41 Million | 10.77 Million | 10.14 Million | 647 Thousand |
| Income Tax Expense | 6.26 Million | 7.56 Million | 2.75 Million | 1.17 Million | 3.66 Million | 700.38 Thousand |
| Earnings before Tax | 1.53 Million | 26.56 Million | 8.06 Million | -2.4 Million | -18.65 Million | -14.06 Million |
| Net Income | -4.93 Million | 17.22 Million | 21.67 Million | -9.56 Million | -28.04 Million | -21.08 Million |
| Earnings Per Share Basic | -0.31 | 1.14 | 1.52 | -0.66 | -1.92 | -1.41 |
| Earnings Per Share Diluted | -0.31 | 1.14 | 1.52 | -0.66 | -1.92 | -1.41 |
| Weighted Average Shares Outstanding | 16.1 Million | 16.42 Million | 16.84 Million | 14.47 Million | 14.63 Million | 15 Million |
| Weighted Average Shares Outstanding (Diluted) | 16.1 Million | 16.42 Million | 16.9 Million | 14.47 Million | 14.63 Million | 15 Million |
| Gross Margin | 0.80 | 0.56 | 0.44 | 0.55 | 0.60 | 0.66 |
| EBIT Margin | 0.21 | 0.39 | 0.27 | 0.12 | -0.12 | -0.20 |
| Profit Margin | -0.05 | 0.16 | 0.28 | -0.13 | -0.39 | -0.27 |
| EBITDA | 19.69 Million | 43.43 Million | 20.9 Million | 7.83 Million | -7.02 Million | -15.25 Million |
| Earnings Before Tax Margin | 0.07 | 0.26 | 0.16 | 0.02 | -0.21 | -0.27 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 72.97 Million | 73.5 Million | 55.86 Million | 111.61 Million | 25.96 Million | 48.05 Million |
| Cost of Revenue | 12.39 Million | 12.49 Million | 23.28 Million | 45.39 Million | 10.81 Million | 20.76 Million |
| Gross Profit | 60.57 Million | 61.01 Million | 32.58 Million | 66.21 Million | 15.14 Million | 27.28 Million |
| Operating Expenses | 13.54 Million | 13.64 Million | 34.86 Million | 53.78 Million | 15.48 Million | 19.91 Million |
| Selling, General and Administrative Expenses | 8.74 Million | 8.8 Million | 22.89 Million | - | 11.09 Million | 10.78 Million |
| Research and Development Expenses | 5.79 Million | 5.84 Million | 11.96 Million | - | 5.56 Million | 9.12 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 25.94 Million | 26.13 Million | 58.14 Million | 99.18 Million | 26.3 Million | 40.68 Million |
| Operating Income | 46.57 Million | 46.91 Million | -2.28 Million | 12.43 Million | -516.43 Thousand | 7.37 Million |
| Interest Expense | 60.96 Thousand | - | - | 8.52 Million | - | 5.07 Million |
| Income Tax Expense | 6.79 Million | 6.84 Million | 4.63 Million | 6.26 Million | 2.15 Million | 2.4 Million |
| Earnings before Tax | 47.53 Million | 47.88 Million | -2.43 Million | 8.78 Million | -1.13 Million | 4.04 Million |
| Net Income | 40.7 Million | 41 Million | -7.29 Million | 1.55 Million | -3.39 Million | 1.63 Million |
| Earnings Per Share Basic | 2.52 | 2.54 | -0.45 | - | -0.21 | 0.10 |
| Earnings Per Share Diluted | 2.52 | 2.54 | -0.45 | - | -0.21 | 0.10 |
| Weighted Average Shares Outstanding | 16.15 Million | 16.15 Million | 16.05 Million | 16.1 Million | 16.06 Million | 16.14 Million |
| Weighted Average Shares Outstanding (Diluted) | 16.15 Million | 16.15 Million | 16.05 Million | 16.14 Million | 16.06 Million | 16.14 Million |
| Gross Margin | 0.83 | 0.83 | 0.58 | 0.59 | 0.58 | 0.57 |
| EBIT Margin | 0.69 | 0.69 | 0.11 | - | 0.12 | 0.31 |
| Profit Margin | 0.56 | 0.56 | -0.13 | 0.01 | -0.13 | 0.03 |
| EBITDA | 50.47 Million | 50.85 Million | 6.07 Million | - | 2.99 Million | 14.97 Million |
| Earnings Before Tax Margin | 0.64 | 0.64 | -0.04 | 0.11 | -0.02 | 0.15 |
007280
084010
EIC
IVITF
002317
AGGI